Laman UtamaEBS • NYSE
add
Emergent Biosolutions Inc
Tutup sebelumnya
$9.88
Julat hari
$9.25 - $9.78
Julat tahun
$1.42 - $15.10
Permodalan pasaran
508.79J USD
Bilangan Purata
1.04J
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
NYSE
Dalam berita
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
(USD) | Sep 2024info | Perubahan T/T |
---|---|---|
Hasil | 293.80J | 8.61% |
Perbelanjaan pengendalian | 92.20J | -3.96% |
Pendapatan bersih | 114.80J | 143.58% |
Margin untung bersih | 39.07 | 140.12% |
Pendapatan bagi setiap syer | 1.37 | — |
EBITDA | 97.70J | 319.31% |
Kadar cukai berkesan | 19.38% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
(USD) | Sep 2024info | Perubahan T/T |
---|---|---|
Pelaburan tunai dan jangka pendek | 149.90J | 70.73% |
Jumlah aset | 1.48B | -21.94% |
Jumlah liabiliti | 969.40J | -18.94% |
Jumlah ekuiti | 508.40J | — |
Syer tertunggak | 54.18J | — |
Harga kepada buku | 1.05 | — |
Pulangan pada aset | 12.03% | — |
Pulangan pada modal | 14.71% | — |
Aliran Tunai
Perubahan bersih dalam tunai
(USD) | Sep 2024info | Perubahan T/T |
---|---|---|
Pendapatan bersih | 114.80J | 143.58% |
Tunai daripada operasi | 153.70J | 156.17% |
Tunai daripada pelaburan | 112.00J | 692.59% |
Tunai daripada pembiayaan | -180.30J | -319.30% |
Perubahan bersih dalam tunai | 85.40J | 10,775.00% |
Aliran tunai bebas | 154.31J | 111.86% |
Perihal
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid.
During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded. Wikipedia
Diasaskan
5 Sep 1998
Ibu pejabat
Tapak web
Pekerja
1,600